(GSK) GSK plc Business Model Canvas Research

GSK plc has 2 strategic collaborations with Relation Therapeutics, one in fibrotic diseases and one in osteoarthritis, expanding its specialty medicine pipeline into two large, high-need areas. The partnerships add external science to GSK’s R&D base and support earlier-stage target discovery in diseases that affect millions of patients worldwide.

• 2 separate Relation collaborations
• Fibrotic disease focus
• Osteoarthritis focus
• Broadens specialty medicine scope

GSK plc’s alliance with Flagship Pioneering is built to find new medicines and vaccines by backing early-stage innovation and platform discovery. It broadens GSK’s external innovation network, with the deal aimed at advancing up to 10 programs from Flagship’s biotech engine into GSK’s pipeline.

• Up to 10 discovery programs
• Focus on medicines and vaccines
• Supports early-stage platform discovery

GSK makes vaccines and medicines at global scale, and its quality systems sit at the core of regulated pharma output. In 2025, this activity helped keep batch release tight and patient safety high across a portfolio that supports sales of £31.4 billion.

• Global supply
• Strict GMP controls
• Batch release discipline
• Patient safety focus

GSK’s Commercial Operations turn R&D into sales by setting prices, managing launches, and securing market access across countries. In 2025, GSK generated more than £31bn in turnover, so execution on reimbursement and local access is a direct revenue lever.

• Drives launch timing and pricing
• Secures payer and country access
• Converts R&D into revenue

GSK plc depends on about 70,000 employees, with researchers, clinicians, and regulatory specialists turning its £6.4 billion 2024 R&D spend into approved medicines and vaccines. This human capital is the key asset for complex development work, because it links lab science, trial design, and compliance across a global pipeline.

• About 70,000 employees
• £6.4 billion R&D spend
• Supports trial and approval work

GSK plc relies on patents, clinical data, and proprietary methods to protect its medicines and vaccines and keep rivals out. This IP base also lifts partnership value, since licensed assets and know-how help GSK share risk, speed development, and defend pricing power.

• Patents protect innovation.
• Data supports regulatory value.
• Know-how strengthens partnerships.

GSK plc uses external partnerships to speed up mRNA, oligonucleotide, and new target discovery, which helps widen pipeline options and share scientific risk. In 2025, GSK reported £31.4 billion in turnover, so these deals are a core way to keep innovation moving without funding every bet alone.

• Speeds discovery through partners
• Shares R&D cost and risk
• Broadens pipeline optionality

GSK serves the United Kingdom, the United States, and international markets, so its medicines and vaccines reach a wider patient base and support steady demand across regions. In 2024, GSK reported £31.4bn in turnover, with the US as its largest market, which shows why global scale matters for commercial relevance.

• Broad access across UK, US, and global markets
• Large reach supports product demand
• Scale strengthens commercial relevance

GSK’s patient support and adherence programs help people stay on chronic therapy, which can lift treatment continuity and outcomes, especially in respiratory and HIV care. In 2025, GSK reported £31.4 billion in revenue, and these long-term disease areas remain central to its specialty portfolio.

• Supports long-term therapy use
• Best fit: respiratory and HIV
• Links care continuity to outcomes

GSK plc keeps co-development partners close through governance, milestones, and shared R&D decisions, so outside science can move into the pipeline faster. This model supports external innovation in areas like vaccines and specialty medicines, where GSK spent £6.4 billion on research and development in 2024.

• Active R&D partner governance
• Milestone-linked decision making
• Shared control of external innovation

Wholesalers and distributors move GSK plc products across geographies, which helps it reach fragmented markets and keep supply steady. GSK reported about £31.4 billion of 2024 revenue, and that scale makes partner-led distribution important for continuity, especially for medicines and vaccines that must stay available.

• Extends reach into fragmented markets
• Supports supply continuity
• Helps cover many geographies

GSK uses field sales teams and digital medical channels to reach healthcare professionals with product data and clinical evidence, which helps speed launch uptake and ongoing adoption. In 2024, GSK reported £31.4 billion in sales, and these channels are key to turning that scale into prescriptions and market share.

• Field reps support face-to-face education.
• Digital tools share evidence fast.
• Both help launches win early traction.

Patients with chronic and infectious diseases are GSK plc’s end users, so demand tracks disease burden: about 39.9 million people lived with HIV, 262 million had asthma, and 390 million had COPD worldwide. Oncology and infection patients also rely on GSK medicines and vaccines, so treatment access and outcomes shape product use.

• HIV, asthma, COPD, oncology, infections
• Global disease burden drives demand
• Patients are the direct end users

Health systems and insurers shape GSK plc access by deciding reimbursement, prior auth, and formulary placement. They judge value, budget impact, and outcomes, so even a strong asset can stall without clear health-economics data; GSK plc reported £31.4bn in 2024 sales, making payer uptake a direct revenue driver.

• Drive access and reimbursement
• Assess value, cost, outcomes
• Fast uptake needs evidence

GSK plc’s regulatory and pharmacovigilance costs stay high because it must monitor safety across a global product base and keep approvals current. In 2025, GSK reported about £31bn in turnover, so the company’s continuous compliance work is not optional: it protects licenses, reduces recall risk, and helps defend product trust.

• Global safety monitoring runs nonstop.
• Compliance work protects approvals.
• High scale makes costs recurring.

GSK plc’s partnership and licensing costs mainly come from milestone payments and shared development spend, especially in external innovation deals that bring in new assets without funding every project alone. These agreements shift part of the R&D burden off GSK, but they also create fixed cash obligations when partners hit clinical or regulatory milestones.

• Milestone payments raise near-term cash outflows
• Shared R&D cuts solo development load
• Licenses add access, but cost money

GSK plc earns collaborative milestone and royalty revenue when external biotech partners advance assets or sell products. In 2024, GSK reported £31.4bn in turnover, and these deals help monetize pipeline and platform access without funding all R&D alone.

• Upfront cash from partner deals
• Milestones tied to trial progress
• Royalties on partner sales
• Uses external biotech collaboration

GSK plc earns global commercial product sales across the United Kingdom, the United States, and international markets, with 2025 sales of £31.4 billion. The United States delivered 52% of sales, Europe 21%, and International 27%, showing how broad distribution and market access lift total turnover.

• 2025 sales: £31.4 billion
• US share: 52%
• Europe share: 21%
• International share: 27%